CYP2J2
From Wikipedia, the free encyclopedia
|
Cytochrome P450, family 2, subfamily J, polypeptide 2
|
||||||||||||||
| Identifiers | ||||||||||||||
| Symbol(s) | CYP2J2; CPJ2 | |||||||||||||
| External IDs | OMIM: 601258 MGI: 1270148 HomoloGene: 68091 | |||||||||||||
|
||||||||||||||
| RNA expression pattern | ||||||||||||||
| Orthologs | ||||||||||||||
| Human | Mouse | |||||||||||||
| Entrez | 1573 | 13110 | ||||||||||||
| Ensembl | ENSG00000134716 | ENSMUSG00000052914 | ||||||||||||
| Uniprot | P51589 | Q8BR78 | ||||||||||||
| Refseq | NM_000775 (mRNA) NP_000766 (protein) |
NM_010008 (mRNA) NP_034138 (protein) |
||||||||||||
| Location | Chr 1: 60.13 - 60.17 Mb | Chr 4: 96.01 - 96.05 Mb | ||||||||||||
| Pubmed search | [1] | [2] | ||||||||||||
Cytochrome P450, family 2, subfamily J, polypeptide 2, also known as CYP2J2, is a human gene.[1]
This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum and is thought to be the predominant enzyme responsible for epoxidation of endogenous arachidonic acid in cardiac tissue.[1]
[edit] References
[edit] Further reading
- Scarborough PE, Ma J, Qu W, Zeldin DC (1999). "P450 subfamily CYP2J and their role in the bioactivation of arachidonic acid in extrahepatic tissues.". Drug Metab. Rev. 31 (1): 205–34. PMID 10065373.
- Capdevila JH, Falck JR, Harris RC (2000). "Cytochrome P450 and arachidonic acid bioactivation. Molecular and functional properties of the arachidonate monooxygenase.". J. Lipid Res. 41 (2): 163–81. PMID 10681399.
- Wu S, Moomaw CR, Tomer KB, et al. (1996). "Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxygenase highly expressed in heart.". J. Biol. Chem. 271 (7): 3460–8. PMID 8631948.
- Zeldin DC, Foley J, Ma J, et al. (1996). "CYP2J subfamily P450s in the lung: expression, localization, and potential functional significance.". Mol. Pharmacol. 50 (5): 1111–7. PMID 8913342.
- Zeldin DC, Foley J, Boyle JE, et al. (1997). "Predominant expression of an arachidonate epoxygenase in islets of Langerhans cells in human and rat pancreas.". Endocrinology 138 (3): 1338–46. PMID 9048644.
- Zeldin DC, Foley J, Goldsworthy SM, et al. (1997). "CYP2J subfamily cytochrome P450s in the gastrointestinal tract: expression, localization, and potential functional significance.". Mol. Pharmacol. 51 (6): 931–43. PMID 9187259.
- Ma J, Ramachandran S, Fiedorek FT, Zeldin DC (1998). "Mapping of the CYP2J cytochrome P450 genes to human chromosome 1 and mouse chromosome 4.". Genomics 49 (1): 152–5. doi:. PMID 9570962.
- Bylund J, Finnström N, Oliw EH (1999). "Gene expression of a novel cytochrome P450 of the CYP4F subfamily in human seminal vesicles.". Biochem. Biophys. Res. Commun. 261 (1): 169–74. doi:. PMID 10405341.
- Gu J, Su T, Chen Y, et al. (2000). "Expression of biotransformation enzymes in human fetal olfactory mucosa: potential roles in developmental toxicity.". Toxicol. Appl. Pharmacol. 165 (2): 158–62. doi:. PMID 10828211.
- King LM, Ma J, Srettabunjong S, et al. (2002). "Cloning of CYP2J2 gene and identification of functional polymorphisms.". Mol. Pharmacol. 61 (4): 840–52. PMID 11901223.
- Matsumoto S, Hirama T, Matsubara T, et al. (2003). "Involvement of CYP2J2 on the intestinal first-pass metabolism of antihistamine drug, astemizole.". Drug Metab. Dispos. 30 (11): 1240–5. PMID 12386130.
- Strausberg RL, Feingold EA, Grouse LH, et al. (2003). "Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.". Proc. Natl. Acad. Sci. U.S.A. 99 (26): 16899–903. doi:. PMID 12477932.
- Marden NY, Fiala-Beer E, Xiang SH, Murray M (2003). "Role of activator protein-1 in the down-regulation of the human CYP2J2 gene in hypoxia.". Biochem. J. 373 (Pt 3): 669–80. doi:. PMID 12737630.
- Pucci L, Lucchesi D, Chirulli V, et al. (2004). "Cytochrome P450 2J2 polymorphism in healthy Caucasians and those with diabetes mellitus.". American journal of pharmacogenomics : genomics-related research in drug development and clinical practice 3 (5): 355–8. PMID 14575523.
- Ota T, Suzuki Y, Nishikawa T, et al. (2004). "Complete sequencing and characterization of 21,243 full-length human cDNAs.". Nat. Genet. 36 (1): 40–5. doi:. PMID 14702039.
- Seubert J, Yang B, Bradbury JA, et al. (2005). "Enhanced postischemic functional recovery in CYP2J2 transgenic hearts involves mitochondrial ATP-sensitive K+ channels and p42/p44 MAPK pathway.". Circ. Res. 95 (5): 506–14. doi:. PMID 15256482.
- Xiao YF, Ke Q, Seubert JM, et al. (2005). "Enhancement of cardiac L-type Ca2+ currents in transgenic mice with cardiac-specific overexpression of CYP2J2.". Mol. Pharmacol. 66 (6): 1607–16. doi:. PMID 15361551.
- Spiecker M, Darius H, Hankeln T, et al. (2005). "Risk of coronary artery disease associated with polymorphism of the cytochrome P450 epoxygenase CYP2J2.". Circulation 110 (15): 2132–6. doi:. PMID 15466638.

